Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah A Scott

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|June 9, 2007
Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitorsMichelle K Clark, Sarah A Scott, Jonathan Wojtkowiak, et al.
Journal of Medicinal Chemistry|August 26, 2010
Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitorRobert R Lavieri, Sarah A Scott, Paige E Selvy, et al.
Journal of Medicinal Chemistry|March 1, 2013
Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cellsMatthew C O'Reilly, Sarah A Scott, Kyle A Brown, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2009
Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificityJana A Lewis, Sarah A Scott, Robert Lavieri, et al.
The Journal of Clinical Investigation|August 14, 2012
FAM83B mediates EGFR- and RAS-driven oncogenic transformationRocky Cipriano, James Graham, Kristy L S Miskimen, et al.
Chemmedchem|September 12, 2014
Discovery of a highly selective PLD2 inhibitor (ML395): a new probe with improved physiochemical properties and broad-spectrum antiviral activity against influenza strainsMatthew C O'Reilly, Thomas H Oguin, Sarah A Scott, et al.
The Journal of Biological Chemistry|July 29, 2014
Phospholipase D facilitates efficient entry of influenza virus, allowing escape from innate immune inhibitionThomas H Oguin, Shalini Sharma, Amanda D Stuart, et al.
The Journal of Biological Chemistry|June 1, 2013
Regulation of phospholipase D activity and phosphatidic acid production after purinergic (P2Y6) receptor stimulationSarah A Scott, Yun Xiang, Thomas P Mathews, et al.
ACS Chemical Biology|November 11, 2014
Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymesSarah A Scott, Cierra T Spencer, Matthew C O'Reilly, et al.
Nature Chemical Biology|January 13, 2009
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasivenessSarah A Scott, Paige E Selvy, Jason R Buck, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|June 9, 2007
Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitorsMichelle K Clark, Sarah A Scott, Jonathan Wojtkowiak, et al.
Journal of Medicinal Chemistry|August 26, 2010
Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitorRobert R Lavieri, Sarah A Scott, Paige E Selvy, et al.
Journal of Medicinal Chemistry|March 1, 2013
Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cellsMatthew C O'Reilly, Sarah A Scott, Kyle A Brown, et al.
Bioorganic & Medicinal Chemistry Letters|March 10, 2009
Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificityJana A Lewis, Sarah A Scott, Robert Lavieri, et al.
The Journal of Clinical Investigation|August 14, 2012
FAM83B mediates EGFR- and RAS-driven oncogenic transformationRocky Cipriano, James Graham, Kristy L S Miskimen, et al.
Chemmedchem|September 12, 2014
Discovery of a highly selective PLD2 inhibitor (ML395): a new probe with improved physiochemical properties and broad-spectrum antiviral activity against influenza strainsMatthew C O'Reilly, Thomas H Oguin, Sarah A Scott, et al.
The Journal of Biological Chemistry|July 29, 2014
Phospholipase D facilitates efficient entry of influenza virus, allowing escape from innate immune inhibitionThomas H Oguin, Shalini Sharma, Amanda D Stuart, et al.
The Journal of Biological Chemistry|June 1, 2013
Regulation of phospholipase D activity and phosphatidic acid production after purinergic (P2Y6) receptor stimulationSarah A Scott, Yun Xiang, Thomas P Mathews, et al.
ACS Chemical Biology|November 11, 2014
Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymesSarah A Scott, Cierra T Spencer, Matthew C O'Reilly, et al.
Nature Chemical Biology|January 13, 2009
Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasivenessSarah A Scott, Paige E Selvy, Jason R Buck, et al.
Pageof 3